Please login to the form below

Not currently logged in
Email:
Password:

ViiV

This page shows the latest ViiV news and features for those working in and with pharma, biotech and healthcare.

Gilead’s Biktarvy gets European approval, setting up battle with GSK

Gilead’s Biktarvy gets European approval, setting up battle with GSK

Juluca, marketed by GSK-led ViiV Healthcare is a two-drug combination which received EU approval just last month, putting the companies into direct competition.

Latest news

More from news
Approximately 30 fully matching, plus 61 partially matching documents found.

Latest Intelligence

  • Stronger together Stronger together

    The top-down approach has certainly been in evidence at ViiV, the joint venture between GlaxoSmithKline, Pfizer and Shionogi, as its CEO Dominique Limet told the eyeforpharma audience. “ ... This year's survey of European patient groups marked the

  • Deal Watch December 2015 Deal Watch December 2015

    2, 075. BMS (HIV business). GSK (ViiV). Acquisition - asset. Acquisition of HIV product pipeline from BMS incl.

  • Understanding the patient ecosystem Understanding the patient ecosystem

    The continued success of the ViiV pharma group, which has three times now been deemed the most reputable and engaged pharma firm in the eyes of patient charities, also highlights how

  • Choices, choices: the rapidly evolving HIV treatment landscape Choices, choices: the rapidly evolving HIV treatment landscape

    With the recent launch of Triumeq from ViiV – whose owner, GSK, brought the first HIV treatment to market in the late 1980s – this looks set to change. ... Viiv's Triumeq is now following a similar pattern. Although it gained EU approval in September

  • Pharma deals during October 2012 Pharma deals during October 2012

    The first is the revised deal between ViiV Healthcare (the speciality HIV company formed by GSK and Pfizer in 2009) and Shionogi. ... Under the new agreement, ViiV Healthcare will acquire the exclusive global rights to the assets in the Shionogi-ViiV

More from intelligence
Approximately 2 fully matching, plus 5 partially matching documents found.

Latest appointments

  • GSK's Deborah Waterhouse to take over from ViiV' Dominique Limet GSK's Deborah Waterhouse to take over from ViiV' Dominique Limet

    GSK's Deborah Waterhouse to take over from ViiV' Dominique Limet. She will become CEO designate at the HIV-focused firm in January. ... He said: “ Establishing and then leading ViiV Healthcare for the past seven years has been an incredible honour and

  • Phil Golz appointed commercial director at HealthUnlocked Phil Golz appointed commercial director at HealthUnlocked

    Phil Golz appointed commercial director at HealthUnlocked. Moves from ViiV Healthcare to join the socialnetwork for health. ... He joins the company from ViiV Healthcare, where he was executive director, and prior to that he served as head of commercial

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 14 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
EY Life Sciences

Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics